✦ LIBER ✦

Immunogenicity and protectivity of a new liposomal hepatitis A vaccine

✍ Scribed by F. Ambrosch; G. Wiedermann; S. Jonas; B. Althaus; B. Finkel; R. Glück; C. Herzog

Book ID: 117432567
Publisher: Elsevier Science
Year: 1997
Tongue: English
Weight: 675 KB
Volume: 15
Category: Article
ISSN: 0264-410X
DOI: 10.1016/s0264-410x(97)00015-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A bacterially expressed particulate hepa

A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates

✍ Shao W. Li; Jun Zhang; Yi M. Li; Shan H. Ou; Guo Y. Huang; Zhi Q. He; Sheng X. G 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 225 KB

Immunogenicity of a hepatitis A virus va

Immunogenicity of a hepatitis A virus vaccine

✍ Bertram Flehmig; Angelika Haage; Mechthild Pfisterer 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 555 KB

Hepatitis A virus (HAV) strain HAV/HFS/GBM was adapted to and grown in human diploid fibroblast cells. The HAV was concentrated by ammonium sulphate precipitation and high-speed centrifugation. The virus was inactivated by beta-propiolacton and purified by sedimentation through a 20% solution of suc

High immunogenicity and good tolerabilit

High immunogenicity and good tolerability of a new hepatitis A vaccine candidate

✍ B.C.A. Langer; A. Lövestad; G.G. Frösner 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 366 KB

Safety and immunogenicity of a new formu

Safety and immunogenicity of a new formulation of an inactivated hepatitis A vaccine

✍ Ron Dagan; David Greenberg; Polina Goldenbertg-Gehtman; Emmanuel Vidor; Philippe 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 160 KB

Immunogenicity and antitumor activity of

Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine

✍ John Samuel; Wladyslaw A. Budzynski; Mark A. Reddish; Lei Ding; Gabrielle L. Zim 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 163 KB 👁 2 views

A human MUC1-transfected mouse mammary adenocarcinoma cell line (GZHI) was used to develop both subcutaneous and intravenous tumor models. A vaccine formulation comprised of a 24 mer (human MUC1) synthetic peptide encapsulated with monophosphoryl lipid A adjuvant (MPLA) in multilamellar liposomes wa

Immunogenicity and safety of a new inact

Immunogenicity and safety of a new inactivated hepatitis a vaccine in a comparative study

✍ Dr. Christian Goilav; Jane Zuckerman; Michael Lafrenz; Emmanuel Vidor; Sabine La 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 668 KB

## Abstract A multicentre, controlled, randomised, open, comparative trial including 839 healthy adult volunteers was carried out in order to compare the immunogenicity and reactogenicity of two vaccines against hepatitis A virus (HAV) during primary immunization and after booster injection. The fi